The DOI matches its Crossref record; 179 of the 181 references it cites were found in a registry or an index.
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [9]
In the citing paper
“Professional society guidelines now recommend GLP-1RA therapy for cardiovascular risk mitigation in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, independent of glucose control or background antihyperglycemic therapy (other diabetes medications being used).”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [15]
In the citing paper
“Society recommendations and guidelines support the concurrent use of GLP-1RAs and SGLT2 inhibitors when needed for adequate glycemic control, but data on whether such combinations may yield incremental cardiovascular advantages are lackingthusfar.15,16,21”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Research works printed but not linked: 8
- Bangalore, 2011, Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials, 2799
- American College of Obstetricians and Gynecologists, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Carter, 2013, Risk of incident diabetes among patients treated with statins: population based study [published correction appears in BMJ 2013;347:f4356], f2610
- Belch, 2008, he prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease, a1840
- Bethel, 2016, Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes, 224
- U.S. Food and Drug Administration, 2008, Guidance for industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
- Rosenstock, 2019, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial, 69
- Rosenstock, 2018, Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk, 39
Cited by
Sorted by citations
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Gomes, M. A. M., Brandão, A. A., Feitosa, A. D. M., Machado, C. A., Poli‐de‐Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,389
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease
Jia, G., & Sowers, J. R. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17981 · Cited by 493
Virani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4182 · Cited by 288
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
An Effective Model of Diabetes Care and Education: The ADCES7 Self-Care Behaviors™
Kolb, L. E. (2021) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721720978154 · Cited by 287
Mosenzon, O., Alguwaihes, A. M., Leon, J. L. A., Bayram, F., Darmon, P., Davis, T. M. E., Dieuzeide, G., Eriksen, K. T., Hong, T., Kaltoft, M. S., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01344-0 · Cited by 259
Diabetes complications in racial and ethnic minority populations in the USA.
Haw, J. S., Shah, M., Turbow, S., Egeolu, M., & Umpierrez, G. (2021) · Current Diabetes Reports · doi:10.1007/s11892-020-01369-x · Cited by 240
Rossing, P. R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Birkenfeld, A. L., McGill, J. B., Rosas, S. E., Joseph, A., Gebel, M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0294 · Cited by 231
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 191
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 182
Adhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer
Guirguis‐Blake, J., Evans, C. V., Perdue, L. A., Bean, S., & Senger, C. A. (2022) · JAMA · doi:10.1001/jama.2022.3337 · Cited by 169
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155
Wang, A., Lv, G., Cheng, X., Ma, X., Wang, W., Gui, J., Hu, J., Lu, M., Chu, G., Chen, J., et al. (2020) · Burns & Trauma · doi:10.1093/burnst/tkaa017 · Cited by 174
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes
Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.10.013 · Cited by 144
Thethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
Kwan, T., Wong, S. S., Hong, Y., Kanaya, A. M., Khan, S. S., Hayman, L. L., Shah, S. H., Welty, F. K., DEEDWANIA, P. C., Khaliq, A., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001145 · Cited by 140
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 148
Alfego, D., Ennis, J. L., Gillespie, B. S., Lewis, M. J., Montgomery, E., Ferrè, S., Vassalotti, J. A., & Letovsky, S. I. (2021) · Diabetes Care · doi:10.2337/dc21-0723 · Cited by 133
Mackey, K., King, V. J., Gurley, S. B., Kiefer, M., Liederbauer, E., Vela, K., Sonnen, P., & Kansagara, D. L. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1515 · Cited by 130
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Avilés-Santa, L. M., Monroig-Rivera, A., Soto-Soto, A., & Lindberg, N. M. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01341-9 · Cited by 145
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Nesti, L., Tricò, D., Mengozzi, A., & Natali, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01294-7 · Cited by 126
Mason, S. A., Keske, M. A., & Wadley, G. D. (2021) · Diabetes Care · doi:10.2337/dc20-1893 · Cited by 139
Deng, X., Zhang, C., Wang, P., Wei, W., Shi, X., Wang, P., Yang, J., Wang, L., Tang, S., Fang, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac210 · Cited by 122
Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.048740 · Cited by 115
Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities
van der Slikke, E. C., An, A. Y., Hancock, R. E. W., & Bouma, H. R. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103044 · Cited by 124
Ciardullo, S., & Perseghin, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154752 · Cited by 112
Risk factors for diabetic foot complications in type 2 diabetes—A systematic review
Rossboth, S., Lechleitner, M., & Oberaigner, W. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.175 · Cited by 134
goFOODTM: An Artificial Intelligence System for Dietary Assessment
Lu, Y. L., Stathopoulou, T., Vasiloglou, M. F., Pinault, L. F., Kiley, C., Spanakis, E. K., & Mougiakakou, S. G. (2020) · Sensors · doi:10.3390/s20154283 · Cited by 108
The Inflammasome in Chronic Complications of Diabetes and Related Metabolic Disorders
Menini, S., Iacobini, C., Vitale, M., & Pugliese, G. (2020) · Cells · doi:10.3390/cells9081812 · Cited by 97
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health
Djuricic, I. D., & Calder, P. C. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-090208 · Cited by 107
Michos, E. D., López-Jiménez, F. A., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 97
Verma, S., McGuire, D. K., Bain, S. C., Bhatt, D. L., Leiter, L. A., Mazer, C. D., Fries, T. M., Pratley, R. E., Rasmussen, S., Vražić, H., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14160 · Cited by 96
ADDENDA-BHS2 trial investigators, Sposito, A. C., Breder, I. S. S., Soares, A., Kimura-Medorima, S. T., Munhoz, D., Cintra, R. M. R., Bonilha, I., de Oliveira, D. C., Breder, J. D. S. C., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01264-z · Cited by 89
Natural antioxidants in diabetes treatment and management: prospects of astaxanthin
Kanwugu, O. N., Glukhareva, T. V., Danilova, I. G., & Kovaleva, E. G. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1881434 · Cited by 93
Zhao, X., He, Q., Zeng, Y., & Cheng, L. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046252 · Cited by 89
Qian, B., Chen, H., Wang, X., Guan, Z., Li, T., Jin, Y., Wu, Y.-L., Wen, Y., Che, H., Kwon, G., et al. (2024) · Patterns · doi:10.1016/j.patter.2024.100929 · Cited by 82
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
High glucose: an emerging association between diabetes mellitus and cancer progression
Supabphol, S., Seubwai, W., Wongkham, S., & Saengboonmee, C. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02096-w · Cited by 80
Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 76
The RESPOND Study Group∗ (2021) · AIDS · doi:10.1097/qad.0000000000002811 · Cited by 73
Leoncini, G., Viazzi, F. C., Cosmo, S. D., Russo, G. T., Fioretto, P., & Pontremoli, R. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00803-3 · Cited by 70
Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction
Sikand, G., & Severson, T. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100106 · Cited by 73
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 65
Somagutta, M. K. R., Agadi, K., Hange, N., Jain, M. S., Batti, E., Emuze, B. O., Amos-Arowoshegbe, E. O., Popescu, S., Hanan, S., Kumar, V. R., et al. (2021) · Cureus · doi:10.7759/cureus.13665 · Cited by 63
Chronic kidney disease in patients with diabetes mellitus
Nordheim, E., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0097 · Cited by 74
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes
Fang, M., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-2304 · Cited by 59
Malik, M. E., Falkentoft, A. C., Jensen, J., Zahir, D., Parveen, S., Alhakak, A., Andersson, C., Petrie, M. C., Sattar, N., McMurray, J. J. V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100617 · Cited by 67
Goh, L. H., Siah, C. J. R., Tam, W., Tai, E. S., & Young, D. Y. L. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02117-w · Cited by 74
Giugliano, D., Longo, M., Maiorino, M. I., Bellastella, G., Chiodini, P., Solerte, S. B., & Esposito, K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108114 · Cited by 63
Goldberg, R. B., Stone, N. J., & Grundy, S. M. (2020) · Diabetes Care · doi:10.2337/dci19-0036 · Cited by 60
The Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 58
Mascolo, A., Scavone, C., Scisciola, L., Chiodini, P., Capuano, A., & Paolisso, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105836 · Cited by 56
Continuous glucose monitoring in the hospital: an update in the era of COVID-19
Gothong, C., Singh, L. G., Satyarengga, M., & Spanakis, E. K. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000693 · Cited by 60
Sarkar, S., & Brown, T. T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01382-8 · Cited by 53
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 49
Foss, R. M., Fischer, K., Lampman, M. A., Laabs, S. B., Halasy, M. P., Allen, S. V., Garrison, G. M., Sobolik, G. J., Bernard, M., Sosso, J. L., et al. (2023) · The Annals of Family Medicine · doi:10.1370/afm.2962 · Cited by 49
Metformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 47
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 44
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 43
Fan, R., Zhang, N., Yang, L., Ke, J., Zhao, D. H., & Cui, Q. (2020) · Scientific Reports · doi:10.1038/s41598-020-71321-2 · Cited by 41
Harms, P. P., van der Heijden, A. A. W. A., Rutters, F., Tan, H. L., Beulens, J. W. J., Nijpels, G., & Elders, P. J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107810 · Cited by 41
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 43
Gao, J., Li, Y., Zhang, Y., Zhan, X., Tian, X., Li, J., Wang, R., He, Y. L., Wang, A., & Wu, S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032604 · Cited by 42
Fonseca, L., Paredes, S., Ramos, H., Oliveira, J. C., & Palma, I. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01292-w · Cited by 39
Gamrat, A., Surdacki, M. A., Chyrchel, B., & Surdacki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072090 · Cited by 40
The Endothelium as a Therapeutic Target in Diabetes: A Narrative Review and Perspective
Adams, J. A., Uryash, A., Lopez, J. R., & Sackner, M. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.638491 · Cited by 38
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Impact of Longitudinal Virtual Primary Care on Diabetes Quality of Care
Lu, A. D., Gunzburger, E. C., Glorioso, T. J., Smith, W. B., Kenney, R. R., Whooley, M. A., & Ho, P. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06547-x · Cited by 37
Williams, A., Shrodes, J. C., Radabaugh, J. N., Braun, A. C., Kline, D., Zhao, S., Brock, G. N., Nolan, T. S., Garner, J. A., Spees, C., et al. (2022) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.07.021 · Cited by 37
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 36
Biscetti, F., Nardella, E., Rando, M. M., Cecchini, A. L., Bonadia, N., Bruno, P., Angelini, F., Stasi, C. D., Contegiacomo, A., Santoliquido, A., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01123-3 · Cited by 33
Chronic Microvascular Complications in Prediabetic States—An Overview
Baranowska-Jurkun, A., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103289 · Cited by 37
Lipid management for cardiovascular risk reduction in type 1 diabetes
Tell, S., Nadeau, K. J., & Eckel, R. H. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000551 · Cited by 30
Castellana, M., Procino, F., Sardone, R., Trimboli, P., & Giannelli, G. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01067-8 · Cited by 31
Jiang, A., Feng, Z., Yuan, L., Zhang, Y., Li, Q., & She, Y. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00652-5 · Cited by 31
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
Riddle, M. C., Gerstein, H. C., Xavier, D., Cushman, W. C., Leiter, L. A., Raubenheimer, P. J., Atisso, C. M., Raha, S., Varnado, O. J., Кониг, М., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab065 · Cited by 31
Angiolillo, D. J., & Capodanno, D. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.12.022 · Cited by 29
Bruemmer, D., & Nissen, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000199 · Cited by 30
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
Jung, C., & Mok, J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.260 · Cited by 28
Leino, A. D., Dorsch, M. P., & Lester, C. A. (2020) · Diabetes Care · doi:10.2337/dc20-1481 · Cited by 28
Batista, D. V., Vieira, C. A. F. D. A., Costa, T. A., & Lima, E. G. (2020) · Diabetology International · doi:10.1007/s13340-020-00473-3 · Cited by 28
Olesen, K. K. W., Gyldenkerne, C., Thim, T., Thomsen, R. W., & Mæng, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001803 · Cited by 32
Thomsen, R. W., Knudsen, J. S., Kahlert, J. A., Baggesen, L. M., Lajer, M., Holmgaard, P., Vedin, O., Ustyugova, A., & Sørensen, H. T. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019356 · Cited by 28
Representation and Extrapolation: Evidence from Clinical Trials
Alsan, M. M., Durvasula, M., Gupta, H., Schwartzstein, J., & Williams, H. (2023) · The Quarterly Journal of Economics · doi:10.1093/qje/qjad036 · Cited by 32
Mosenzon, O., Bain, S. C., Heerspink, H. J. L., Idorn, T., Mann, J. F. E., Persson, F., Pratley, R. E., Rasmussen, S., Rossing, P. R., von Scholten, B. J., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14126 · Cited by 26
Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
Rotkvić, P. G., Berković, M. C., Bulj, N., Rotkvić, L., & Ćelap, I. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i7.269 · Cited by 28
Shi, A., Xie, P., Nielsen, L. L., Skjøth, T. V., He, X., & Haugaard, S. P. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01548-y · Cited by 29
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 29
Neto, J. C. G. L., Damasceno, M. M. C., Ciol, M. A., de Freitas, R. W. J. F., de Araújo, M. F. M., Teixeira, C. R. D. S., Carvalho, G. C. N., Lisboa, K. W. D. S. C., Marques, R. L. L., Alencar, A. M. P. G., et al. (2021) · Journal of the American Nutrition Association · doi:10.1080/07315724.2021.1878967 · Cited by 27
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population
Ciardullo, S., Rea, F., Cannistraci, R., Muraca, E., Perra, S., Zerbini, F., Mortara, A., & Perseghin, G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01671-w · Cited by 27
Metadata
- Authors
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S111-S134
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254135372
- Cited by
- 487
- References
- 181
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 44 · 2023: 61 · 2022: 89 · 2021: 137 · 2020: 131
- FWCI
- 72.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care
- MeSH terms
- Heart Disease Risk Factors, Cardiovascular Diseases, Diabetes Mellitus, Diabetic Angiopathies, Endocrinology, Humans, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
